An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and TB-500. The panel rejected emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem's stock remained stable after the vote. A recent study indicated peptides may aid treatment of antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for expanded access to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how policymakers view specialty peptide therapies, which have drawn steady interest from users seeking alternatives to traditional drugs. Researchers say peptide treatments could change approaches to resistant infections, though concerns about consistency persist. The committee's endorsement of four peptides paves the way for more broad prescribing, even as critics warn of limited evidence. Market watchers note that peptide-focused companies may see increased investor attention following the panel's decision. The rejection of emideltide, meanwhile, signals the FDA's cautious stance on particular peptide candidates.